Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
This study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial to compare the efficacy and safety of celecoxib 400mg QD versus placebo in reducing the occurrence of new colorectal adenomas post-polypectomy at Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.
Colorectal Adenoma
DRUG: Celecoxib
To evaluate the effects of celecoxib in reducing the proportion of subjects with new colorectal adenomas post baseline polypectomy after Month 13 (Year 1) and Month 37 (Year 3) of study drug administration., 3 years
The number of colorectal adenomas in study subjects, 3 years|the histopathologic grade of colorectal adenomas, 3 years|the size of colorectal adenomas measured after one year and three years of study drug use., 3 years
This study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial to compare the efficacy and safety of celecoxib 400mg QD versus placebo in reducing the occurrence of new colorectal adenomas post-polypectomy at Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.